Exxon, AbbVie, Chevron, Home Depot, Rivian Insider Shock - TipRanks

Munich Reinsurance Co Stock Corp in Munich Invests $47.60 Million in AbbVie Inc. $ABBV - MarketBeat

Orleans Capital Management Corp LA Trims Stock Holdings in AbbVie Inc. $ABBV - MarketBeat

Neuberger Berman Group LLC Has $275.06 Million Stake in AbbVie Inc. $ABBV - MarketBeat

Guardian Capital LP Grows Position in AbbVie Inc. $ABBV - MarketBeat

Blair William & Co. IL Has $292.57 Million Position in AbbVie Inc. $ABBV - MarketBeat

Friday Wyckoff scan — market went almost fully neutral after the selloff

Top AbbVie Executive Executes Major Insider Stock Sale - TipRanks

Is AbbVie (ABBV) Still Priced Attractively After Its Strong Multi Year Share Price Run - Yahoo Finance Singapore

Is AbbVie (ABBV) Still Priced Attractively After Its Strong Multi Year Share Price Run - Yahoo Finance

AbbVie (NYSE:ABBV) SVP David Ryan Purdue Sells 5,230 Shares - MarketBeat

AbbVie (ABBV): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance

Super Bowl, Winter Olympics defined TV drug ad spending in February, led by AbbVie’s Rinvoq - Fierce Pharma

AbbVie (ABBV) Up 6.1% Since Last Earnings Report: Can It Continue? - Yahoo Finance

AbbVie (ABBV) Up 6.1% Since Last Earnings Report: Can It Continue? - Yahoo Finance Singapore

These 3 Cash Flow Machines Provide Stability in Uncertain Markets

Will AbbVie's Neuroscience Segment Continue to Aid Top Line in 2026? - The Globe and Mail

Suresh Babu appointed as Business Unit Director – Eye Care at AbbVie India - Veloxx media

Will AbbVie's Neuroscience Segment Continue to Aid Top Line in 2026? - TradingView

Will AbbVie's Neuroscience Segment Continue to Aid Top Line in 2026? - Yahoo Finance

Edgar Lomax Co. VA Reduces Stock Position in AbbVie Inc. $ABBV - MarketBeat

Crossmark Global Holdings Inc. Raises Holdings in AbbVie Inc. $ABBV - MarketBeat

Berry Wealth Group LP Lowers Stake in AbbVie Inc. $ABBV - MarketBeat

AbbVie Expands US AI Manufacturing As Risankizumab Trial Supports Valuation Gap - simplywall.st

I scanned 213 US stocks for institutional buying patterns today, here's what showed up

AbbVie to invest $380 million in North Chicago campus to make next generation medicines - Daily Herald

AbbVie (ABBV) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance

Evercore ISI Adjusts AbbVie Price Target to $233 From $228, Maintains Outperform Rating - marketscreener.com

AbbVie (ABBV) Completes $7.75 Billion Notes Offering - GuruFocus

GW&K Investment Management LLC Sells 6,207 Shares of AbbVie Inc. $ABBV - MarketBeat

Prostate Health Market Is Going to Boom |• AbbVie • Astellas Pharma - openPR.com

BAX Antibody Market Set for Explosive Growth | AbbVie • Amgen • Bristol-Myers Squibb - openPR.com

Cytokines Market Global Forecast 2026-2032: Precise Treatments, Strategic Partnerships, and Supply Chain Resilience Fueling the $95+ Billion Market

(ABBV) Risk Channels and Responsive Allocation - Stock Traders Daily

AbbVie Completes $8 Billion Senior Notes Financing Offering - TipRanks

Assessing AbbVie (ABBV) Valuation After Positive Phase 3 Crohn’s Disease Trial Results - Yahoo Finance

AbbVie: Stabilizes Near $233 While Testing Resistance - Seeking Alpha

AbbVie Advances Venetoclax Into Rare Blood Cancers With New Phase 2 Study - TipRanks

My Official $SCHD Q1 Payout Estimate drops later today! 💰 Before I reveal it… what do you think $SCHD Q1 dividend growth will come in at? Here’s all the raises and cuts we’re working with right now👇 $SCHD Q1 2026 Dividend Growth Update As of Mar 4, 2026 EX DIVIDEND: 3/25 PA

AbbVie: The Only Big Pharma Stock I'd Consider a Buy‑and‑Never‑Sell - Yahoo Finance

AbbVie: The Only Big Pharma Stock I'd Consider a Buy‑and‑Never‑Sell - The Motley Fool

AbbVie stock price forecast: Stabilizes near $233 while testing resistance - Traders Union

ALLERGAN AESTHETICS HIGHLIGHTS MEDICAL WEIGHT LOSS (MWL) DATA AND THE CHANGING PROFILE OF PATIENTS - AbbVie News Center

Griffith & Werner Inc. Invests $2.64 Million in AbbVie Inc. $ABBV - MarketBeat

Picton Mahoney Asset Management Has $25.14 Million Stake in AbbVie Inc. $ABBV - MarketBeat

How Positive Crohn’s Phase 3 Data for SKYRIZI Could Impact AbbVie (ABBV) Investors - simplywall.st

Dimensional Fund Advisors LP Has $2.06 Billion Position in AbbVie Inc. $ABBV - MarketBeat

Cresset Asset Management LLC Sells 15,199 Shares of AbbVie Inc. $ABBV - MarketBeat

Top AbbVie Insider Executes Major Multi-Million Dollar Stock Sale - TipRanks

Perry Siatis Sells 18,668 Shares of AbbVie Inc (ABBV) - GuruFocus

AbbVie (ABBV) EVP Roopal Thakkar reports tax-withholding share disposition - Stock Titan

Can I get to VP/director level roles without a PhD in big pharma

AbbVie CEO reports tax-withholding share disposition | ABBV SEC Filing - Form 4 - Stock Titan

AbbVie (NYSE: ABBV) EVP reports tax-withholding share disposition - Stock Titan

AbbVie (NYSE: ABBV) EVP Perry Siatis sells 18,668 shares - Stock Titan

AbbVie (ABBV) CFO uses 21,638 shares to cover tax withholding - Stock Titan

AbbVie (ABBV) SVP Purdue disposes 2,692 shares for tax withholding - Stock Titan

AbbVie (ABBV) EVP logs 16,309-share tax-withholding disposition in Form 4 - Stock Titan

AbbVie (NYSE: ABBV) EVP uses shares to cover tax withholding - Stock Titan

PRESCRIPTION DRUGS—M.D. Tenn.: Court rejects AbbVie’s challenge to Tennessee contract pharmacy law - VitalLaw.com

AbbVie (NYSE:ABBV) Expansion Boosts Supply Resilience For Immunology Medicines S&P 500 - Kalkine Media

AbbVie at TD Cowen: Strategic Insights and Growth Outlook - Investing.com

March 3 Business Watch: Lyondell cuts sustainability goals; AbbVie to invest in drug chemicals - C&EN

AbbVie to Present at the Leerink Partners Global Healthcare Conference - Investing News Network

ABBV: Strong R&D pipeline and high single-digit growth projected through 2029, driven by innovation - TradingView

Victory Capital Management Inc. Buys 120,490 Shares of AbbVie Inc. $ABBV - MarketBeat

State Farm Mutual Automobile Insurance Co. Sells 69,551 Shares of AbbVie Inc. $ABBV - MarketBeat

Hear AbbVie management live at Leerink global healthcare conference - Stock Titan

Level Four Advisory Services LLC Trims Stock Holdings in AbbVie Inc. $ABBV - MarketBeat

AbbVie Hits $31 Billion in Skyrizi and Rinvoq Sales - TIKR.com

Fisher Asset Management LLC Decreases Holdings in AbbVie Inc. $ABBV - MarketBeat

CI Investments Inc. Has $41.19 Million Stake in AbbVie Inc. $ABBV - MarketBeat

AbbVie Expands Rare Oncology And Immunology With New U.S. Manufacturing Investment - simplywall.st

AbbVie reports ‘positive’ results from Phase 3 AFFIRM study of Skyrizi - TipRanks

AbbVie to invest $380M in new North Chicago API manufacturing facilities - Chicago Construction News

AbbVie’s New Data And Approval Test Growth And Valuation Story - Yahoo Finance

OSE reshuffles pipeline amidst setbacks on Boehringer, AbbVie partnered programmes - FirstWord Pharma

ABBV (NYSE: ABBV) Form 144: Director sale of 22,381 shares noted - Stock Titan

AbbVie Invests $380M to Expand US Manufacturing Facilities - Powder & Bulk Solids

Why AbbVie Stock May Be the Ultimate Option for Dividend Investors - The Globe and Mail

FDA Grants Orphan Drug Status to AbbVie's (ABBV) Neuroendocrine Carcinoma Treatment - GuruFocus

AbbVie Says 55% Of Crohn's Patients Reached Remission With Skyrizi, Bolsters Competitive Positioning Against Johnson & Johnson

Why AbbVie Stock May Be the Ultimate Option for Dividend Investors - Yahoo Finance

Why AbbVie Stock May Be the Ultimate Option for Dividend Investors - Nasdaq

Why AbbVie Stock May Be the Ultimate Option for Dividend Investors - The Motley Fool

William Blair Maintains AbbVie(ABBV.US) With Buy Rating - 富途牛牛

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® Subcutaneous Induction in Patients with Crohn's Disease - Investing News Network

AbbVie (ABBV) Reports Positive Phase 3 Results in Crohn's Diseas - GuruFocus

AbbVie Inc. (ABBV) Stock Analysis: A Healthcare Giant With A 7.16% Potential Upside - DirectorsTalk Interviews

AbbVie’s Skyrizi shows positive results in Crohn’s disease trial - Investing.com India

AbbVie’s Skyrizi shows positive results in Crohn’s disease trial - Investing.com

Abbvie Announces Positive Topline Results From Phase 3 Affirm Study Evaluating Skyrizi® (Risankizumab) Subcutaneous Induction In Patients With Crohn's Disease - TradingView

Crohn's patients see higher remission with AbbVie's SKYRIZI shot - Stock Titan

AbbVie Inc. $ABBV Shares Purchased by Elo Mutual Pension Insurance Co - MarketBeat

AbbVie Inc. $ABBV Stock Holdings Trimmed by Laurel Wealth Advisors LLC - MarketBeat

Bahl & Gaynor Inc. Has $730.34 Million Stock Holdings in AbbVie Inc. $ABBV - MarketBeat

Continuous Manufacturing Market Trends and Global Forecasts, 2035 Featuring Key Players - AbbVie, Abzena, AGC Biologics, Boehringer Ingelheim, Corden Pharma, Glatt, Kaneka, Phlow, and Wuxi Biologics - Yahoo Finance UK

Is AbbVie Inc. (ABBV) One of the Best Cancer Stocks to Invest In Now? - Finviz

AbbVie Inc. $ABBV Shares Sold by 111 Capital - MarketBeat

Is AbbVie Inc. (ABBV) One of the Best Cancer Stocks to Invest In Now? - Insider Monkey

Is AbbVie Inc. (ABBV) One of the Best Cancer Stocks to Invest In Now? - Yahoo Finance

$SLS (Deepest Due Diligence for REGAL Trial) (From a Deep Value Investor)

KSA Market just dropped 2%, are US stocks next?

Is AbbVie Inc. (ABBV) One of the Best Cancer Stocks to Invest In Now? - Bitget

AbbVie Inc. $ABBV Shares Sold by R Squared Ltd - MarketBeat

AbbVie Inc. $ABBV Shares Sold by APG Asset Management N.V. - MarketBeat

Uber, Verizon, AbbVie, IBM and McDonald’s Insider Shake-Up - TipRanks